HOPHF (Hemogenyx Pharmaceuticals) Total Assets: $5.59 Mil (As of Dec. 2025)


HOPHF Hemogenyx Pharmaceuticals PLC HOPHF
31 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals Total Assets?

Hemogenyx Pharmaceuticals HOPHF 31 Total Assets is $5.59 Mil as of Dec. 2025. GuruFocus rates HOPHF with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Hemogenyx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $5.59 Mil.

During the past 12 months, Hemogenyx Pharmaceuticals's average Total Assets Growth Rate was -36.10% per year. During the past 3 years, the average Total Assets Growth Rate was -17.20% per year. During the past 5 years, the average Total Assets Growth Rate was 26.60% per year. During the past 10 years, the average Total Assets Growth Rate was 44.80% per year.

During the past 11 years, Hemogenyx Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 141.90%. The lowest was -17.20%. And the median was 40.10%.

Total Assets is connected with ROA %. Hemogenyx Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was -259.93%. Total Assets is also linked to Revenue through Asset Turnover. Hemogenyx Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Hemogenyx Pharmaceuticals  (OTCPK:HOPHF) Total Assets Explanation

Total Assets is connected with ROA %.

Hemogenyx Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-12.734/( (4.208+5.59)/ 2 )
=-12.734/4.899
=-259.93 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Hemogenyx Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (4.208+5.59)/ 2 )
=0/4.899
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Hemogenyx Pharmaceuticals Total Assets Related Terms

Hemogenyx Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals Total Assets Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.33 8.64 7.73 5.33 5.59

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.73 7.78 5.33 4.21 5.59
HOPHF
31GF Score
Hemogenyx Pharmaceuticals PLC HOPHF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Hemogenyx Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=1.531+4.058
=5.59

Hemogenyx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=1.531+4.058
=5.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $5.59 Mil mean?
Hemogenyx Pharmaceuticals (HOPHF) has a Total Assets of $5.59 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Hemogenyx Pharmaceuticals and its competitors.
Is Hemogenyx Pharmaceuticals' Total Assets too high?
Hemogenyx Pharmaceuticals' current Total Assets is $5.59 Mil. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' Total Assets compare to VRTX and REGN?
Hemogenyx Pharmaceuticals' Total Assets of $5.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current Total Assets is $5.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current Total Assets of $5.59 Mil. The current Total Assets is $5.59 Mil. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current Total Assets is $5.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Other Exchanges HEMO:UK
Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for HOPHF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price